<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Bipolar Disord</journal-id><journal-id journal-id-type="iso-abbrev">Int J Bipolar Disord</journal-id><journal-title-group><journal-title>International Journal of Bipolar Disorders</journal-title></journal-title-group><issn pub-type="epub">2194-7511</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25505693</article-id><article-id pub-id-type="pmc">4224669</article-id><article-id pub-id-type="publisher-id">14</article-id><article-id pub-id-type="doi">10.1186/s40345-014-0014-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bourin</surname><given-names>Michel S</given-names></name><address><email>Michel.Bourin@univ-nantes.fr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Severus</surname><given-names>Emanuel</given-names></name><address><email>Emanuel.Severus@uniklinikum-dresden.de</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Schronen</surname><given-names>Juan P</given-names></name><address><email>jschron@iafrica.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Gass</surname><given-names>Peter</given-names></name><address><email>Peter.Gass@zi-mannheim.de</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Szamosi</surname><given-names>Johan</given-names></name><address><email>johan.szamosi@telia.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Hans</given-names></name><address><email>eriksson_lund@hotmail.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Chandrashekar</surname><given-names>Hongally</given-names></name><address><email>hongally.chandrashekar@gmail.com</email></address><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Department of Pharmacology, Faculty of Medicine, University of Nantes, 98, rue Joseph Blanchart, 44100 Nantes, France </aff><aff id="Aff2"><label/>Department of Psychiatry and Psychotherapy, Technical University of Dresden, Dresden, Germany </aff><aff id="Aff3"><label/>Cape Trial Centre, Cape Town, South Africa </aff><aff id="Aff4"><label/>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany </aff><aff id="Aff5"><label/>AstraZeneca R&#x00026;D, S&#x000f6;dert&#x000e4;lje, Sweden </aff><aff id="Aff6"><label/>Bangalore Medical College and Research institute, Victoria Hospital, Bangalore, India </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>2</volume><elocation-id>14</elocation-id><history><date date-type="received"><day>9</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Bourin et al.; licensee Springer. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><abstract id="Abs1"><p>Quetiapine extended release (XR) and lithium are treatments with proven efficacy in acute mania. This randomized study evaluated the efficacy and safety of lithium or placebo as add-on to quetiapine XR in adult patients with manic or mixed symptoms of bipolar I disorder. In this 6-week, double-blind study (Trial D144AC00003), adult patients with <italic>DSM-IV-TR-</italic>diagnosed bipolar I disorder (current episode manic or mixed), a Young Mania Rating Scale (YMRS) total score &#x02265;20, and score &#x02265;4 on two of four core YMRS items were administered quetiapine XR (400 to 800&#x000a0;mg/day) and randomly assigned to receive add-on lithium (600 to 1,800&#x000a0;mg/day) or placebo. The primary efficacy end point was change in the YMRS total score from baseline to day 43, analyzed using a mixed-model for repeated measures (MMRM) approach. Secondary efficacy and safety end points were also measured. Rating scales were administered by trained staff. Three hundred fifty-six patients treated with quetiapine XR were randomized to add-on lithium (<italic>n</italic>&#x02009;=&#x02009;173) or placebo (<italic>n</italic> = 183). Two hundred ninety-one patients (81.7%) completed the study. At day 43, least squares mean change in YMRS total score was &#x02212;22.8 for add-on lithium and &#x02212;20.1 for add-on placebo, a statistically significant treatment group difference of &#x02212;2.69 (<italic>p</italic> &#x0003c; 0.001). On secondary measures, add-on lithium was associated with significant improvements in response, remission, illness severity, and overall illness versus add-on placebo (<italic>p</italic> &#x0003c; 0.05). The number needed to treat was 9.1 for response and 7.9 for remission for add-on lithium compared with add-on placebo. Lithium in combination with quetiapine XR was generally well tolerated, with a similar profile to quetiapine XR in combination with placebo. The addition of lithium to quetiapine XR therapy was associated with significantly greater efficacy than placebo as add-on and was generally well tolerated in patients with acute bipolar I mania. This study was registered under Clinicaltrials.gov Identifier <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00931723?term=NCT00931723&#x00026;rank=1">NCT00931723</ext-link>.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s40345-014-0014-9) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bipolar mania</kwd><kwd>Lithium</kwd><kwd>Quetiapine XR</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Bipolar disorder is a complex, debilitating illness that typically follows a chronic and recurrent course. Manic, depressed, or mixed symptoms range in severity and rate of onset and in their most extreme forms require hospitalization (Sanchez-Moreno et al. <xref ref-type="bibr" rid="CR29">2009</xref>).</p><p>Given the severe impact and rapid onset of manic symptoms in many patients, prompt and effective control of symptoms is a primary treatment goal (Garlow <xref ref-type="bibr" rid="CR10">2008</xref>; Oral <xref ref-type="bibr" rid="CR22">2005</xref>). Guidelines typically recommend lithium, divalproex, or an atypical antipsychotic in the treatment of acute mania, frequently as monotherapy initially, with combination therapy in cases of inadequate response (Connolly and Thase <xref ref-type="bibr" rid="CR6">2011</xref>; Goodwin <xref ref-type="bibr" rid="CR12">2009</xref>; Grunze et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Nivoli et al. <xref ref-type="bibr" rid="CR20">2011</xref>; Yatham et al. <xref ref-type="bibr" rid="CR45">2009</xref>). Guidelines also recommend combination therapy as first-line treatment for severe manic symptoms (Goodwin <xref ref-type="bibr" rid="CR12">2009</xref>; Grunze et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Nivoli et al. <xref ref-type="bibr" rid="CR20">2011</xref>). However, there is a lack of evidence to support the efficacy and safety of many combination therapies, and not all agents demonstrating antimanic efficacy as monotherapy offer additional efficacy and acceptable tolerability when used in combination (Brooks et al. <xref ref-type="bibr" rid="CR5">2011</xref>; Geoffroy et al. <xref ref-type="bibr" rid="CR11">2012</xref>; Sachs and Gardner-Schuster <xref ref-type="bibr" rid="CR27">2007</xref>; Smith et al. <xref ref-type="bibr" rid="CR33">2007</xref>).</p><p>Quetiapine extended release (quetiapine XR) demonstrates efficacy as monotherapy in acute mania (Cutler et al. <xref ref-type="bibr" rid="CR7">2011</xref>) and bipolar depression (Suppes et al. <xref ref-type="bibr" rid="CR37">2010</xref>). Yatham et al. (<xref ref-type="bibr" rid="CR44">2004</xref>) previously reported that quetiapine immediate release (IR) added to lithium or divalproex provided superior efficacy in treating mania when compared with lithium or divalproex alone. The potential benefits of adding lithium to quetiapine XR have not previously been investigated. The current study compared the efficacy and safety of lithium versus placebo as add-on to quetiapine XR in adults with bipolar I disorder with a current or recent episode of severe manic or mixed symptoms.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was a 6-week, multicenter, double-blind, randomized, parallel-group placebo-controlled study (Trial D144AC00003; Clinicaltrials.gov ID: NCT00931723), conducted at 38 study centers in eight countries (Belgium, Bulgaria, Germany, India, Poland, Russia, South Africa, and Ukraine) between June 24, 2009 and November 22, 2010. The study included an enrollment period (with medication washout for 7 to 28 days, according to medication) and a 6-week treatment period, when quetiapine XR was administered as flexible dose to all patients. Patients were randomly assigned in a 1:1 ratio to receive, in addition, either flexible-dose lithium or placebo at the start of treatment. Following mandatory hospitalization during randomization, patients were permitted to continue study treatment as outpatients.</p><p>The study was performed in agreement with the ethical principles of the Declaration of Helsinki and was consistent with the International Conference on Harmonization (ICH)/Good Clinical Practice (GCP). Written informed consent was provided by all patients.</p></sec><sec id="Sec4"><title>Patient population</title><p>Males or females aged 18 to 65&#x000a0;years with a <italic>Diagnostic and Statistical Manual for Metal Disorders, Fourth Edition, Text Revision</italic> (<italic>DSM-IV-TR)</italic> diagnosis of bipolar I disorder (most recent episode manic or mixed) (American Psychiatric Association <xref ref-type="bibr" rid="CR1">2000</xref>), confirmed by the Structured Clinical Interview for <italic>DSM-IV</italic> (First et al. <xref ref-type="bibr" rid="CR9">2007</xref>), were eligible for inclusion. Patients were required to have a Young Mania Rating Scale (YMRS) (Young et al. <xref ref-type="bibr" rid="CR46">1978</xref>) total score &#x02265;20 and &#x02265;4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior), a Clinical Global Impressions for Bipolar Disorder (CGI-BP) (Spearing et al. <xref ref-type="bibr" rid="CR34">1997</xref>) score &#x02265;4 (i.e., moderately ill), and to have experienced &#x02265;1 manic or mixed episode (other than the current episode) in the past 5&#x000a0;years.</p><p>Key exclusion criteria included current <italic>DSM-IV-TR</italic> Axis I disorders other than bipolar mania; &#x0003e;8 mood episodes within the previous 12&#x000a0;months; mania-like syndrome associated with a medical condition or treatment, substance abuse, or withdrawal; continuous hospitalization for an acute episode of bipolar mania for &#x0003e;3&#x000a0;weeks before randomization; current substance dependence or abuse; current serious suicidal or homicidal risk; or history of nonresponse to study treatments.</p><p>The use of an antipsychotic other than quetiapine, mood stabilizer, antidepressant, anxiolytic, hypnotic, other psychoactive drug, or inducer/inhibitor of cytochrome P 3A4 enzymes was prohibited within 7 to 28 days before randomization. Nonpsychoactive and anticholinergic medications were allowed during the study, as were zolpidem tartrate (maximum 10&#x000a0;mg/day), zaleplon (20&#x000a0;mg/day), zopiclone (7.5&#x000a0;mg/day), chloral hydrate (1&#x000a0;g/day), and lorazepam (2&#x000a0;mg/day).</p></sec><sec id="Sec5"><title>Study treatments</title><p>Open-label quetiapine XR was administered once-daily in the evening, at a starting dose of 300&#x000a0;mg/day on day 1, increasing to 600&#x000a0;mg/day on day 2, and adjusted between 400 and 800&#x000a0;mg/day from day 3 onward depending on efficacy and tolerability, in agreement with prescribing guidelines (Seroquel XR (quetiapine fumarate) <xref ref-type="bibr" rid="CR30">2013</xref>). For patients who received quetiapine prior to the study, the existing dose was administered on day 1 and increased to 600&#x000a0;mg at day 2 if the previous dose was lower.</p><p>Patients were treated with lithium or placebo twice daily. Lithium (immediate release) was administered at a starting dose of 600&#x000a0;mg on days 1 and 2, increasing to 900&#x000a0;mg/day on days 3 to 8. Lithium (or placebo) dosing was adjusted (range, 600 to 1,800&#x000a0;mg/day) from day 9 at the discretion of the investigator to minimize side effects or achieve target trough concentrations of 0.8 to 1.2&#x000a0;mEq/L. On days 8, 15, 22, 29, and 43, lithium was administered after serum lithium sampling. On each occasion that a lithium dose recommendation was sent for a patient randomized to lithium, a matching sham recommendation was sent to non-lithium patients in relation to the dose of placebo capsule.</p><p>The lithium and placebo capsules were identical in appearance, smell, and taste to maintain blinding. In addition, blood samples were drawn from all patients (whether treated with lithium or placebo) on days 8, 15, 22, 29, and 43 for determination of trough serum lithium concentrations.</p></sec><sec id="Sec6"><title>Efficacy assessments</title><p>The primary outcome measure was change in YMRS total score from baseline to day 43. Secondary outcome measures included changes to day 43 in scores for individual YMRS items, Clinical Global Impressions for Bipolar Disorder-Severity of Illness (CGI-BP-S), CGI-BP-Change (CGI-BP-C) (Spearing et al. <xref ref-type="bibr" rid="CR34">1997</xref>), Positive and Negative Syndrome Scale (PANSS) total and activation and positive subscales (Kay et al. <xref ref-type="bibr" rid="CR17">1987</xref>), and Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) (Montgomery and Asberg <xref ref-type="bibr" rid="CR18">1979</xref>). Response (i.e., &#x02265;50% reduction in YMRS total score to day 43), remission (YMRS total score &#x02264;12 at day 43), and improvement in overall bipolar illness (CGI-BP-C score of &#x02018;much&#x02019; or &#x02018;very much&#x02019; improved overall bipolar illness at day 43) were also assessed, using conventional cutoff criteria (Bourin and Thibaut <xref ref-type="bibr" rid="CR3">2013</xref>). Rating scales were administered by staff who were trained in their use and who were blinded to study treatments.</p></sec><sec id="Sec7"><title>Safety and tolerability assessments</title><p>Safety and tolerability assessments included treatment-emergent adverse events (TEAEs; incidence and severity), adverse event (AE)-related withdrawals, and changes from baseline in vital signs, laboratory parameters, and body weight. Extrapyramidal symptoms (EPS) were assessed by TEAEs, changes in EPS rating scales (Simpson-Angus Scale [SAS] (Simpson and Angus <xref ref-type="bibr" rid="CR32">1970</xref>), Abnormal Involuntary Movement Scale [AIMS] (Guy <xref ref-type="bibr" rid="CR15">1976</xref>), and Barnes Akathisia Rating Scale (BARS) (Barnes <xref ref-type="bibr" rid="CR2">1989</xref>)), worsening of SAS, AIMS, or BARS score category, and initiation of anticholinergic medication for EPS. Suicidality was assessed by TEAEs and prospective use of the Columbia-Suicide Severity Rating Scale (C-SSRS), with mapping of C-SSRS responses also to the Columbia-Classification Algorithm for Suicide Assessment (C-CASA) (Posner et al. <xref ref-type="bibr" rid="CR24">2007</xref>, <xref ref-type="bibr" rid="CR25">2011</xref>). Other TEAEs of special interest, besides EPS and suicidality, included somnolence, diabetes mellitus, QTc prolongation, neutropenia/agranulocytosis, and depression/depressed mood.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>It was estimated that 166 evaluable patients were required in each treatment group to reject the null hypothesis of no difference with a power of 80% when using a two-sided <italic>t</italic>-test at an overall type I error rate of 5%, assuming a true effect of four points on YMRS between the two groups and a standard deviation (SD) of 9.</p><p>Efficacy analyses were performed on the modified intent-to-treat analysis set (ITT), which included all randomized patients who received &#x02265;1 dose of quetiapine XR and lithium or placebo and had a baseline YMRS score and &#x02265;1 post-baseline score assessment. Group differences in change in efficacy rating scale score were analyzed using a mixed-model for repeated measures (MMRM) approach; while group differences in response, remission, and overall bipolar illness were tested using generalized estimating equations. The robustness of the primary study analysis was tested using the per-protocol (PP) set (i.e., all ITT patients without major protocol violations or deviations affecting efficacy) and in the ITT set using robust variance estimates, as well as by analysis of covariance (ANCOVA) modeling using last observation carried forward (LOCF) methodology, including baseline YMRS total score as covariate, treatment group as fixed effect, and centers as random effect.</p><p>Safety variables were evaluated on the safety analysis set (all randomized patients who received at least one dose of study medication) and are presented using descriptive statistics.</p><p>All statistical comparisons were based on a two-sided test using a significance level of 5%. Analyses were performed with SAS&#x000ae; software, Version 9.2 or higher (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><p>Overall, 441 patients were enrolled and screened, of whom 356 received quetiapine XR and were randomized to add-on treatment with lithium (<italic>n</italic> = 173) or placebo (<italic>n</italic> = 182) (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The most common reason for nonrandomization was incorrect enrollment due to patients not meeting the inclusion criteria (<italic>n</italic> = 57). The majority of patients (91.0%) received study treatment as outpatients. Forty-four of the patients (12.4%) were diagnosed with severe mania and psychotic features at baseline.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Patient disposition.</bold>
<sup><bold>a</bold></sup>
<bold>One randomized patient did not receive study treatment.</bold>
</p></caption><graphic xlink:href="40345_2014_14_Fig1_HTML" id="MO1"/></fig></p><p>The ITT and safety analysis sets comprised 349 and 356 patients, respectively. The PP set included 143 patients (<italic>n</italic> = 45, add-on lithium; <italic>n</italic> = 98, add-on placebo). Failure to achieve lithium concentrations within the target range (<italic>n</italic> = 112 patients) was the most common protocol deviation. Baseline demographics and disease characteristics were generally similar between the treatment groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Mean YMRS total scores at baseline were 29.9 and 30.0 in the add-on lithium and add-on placebo groups, respectively, indicating a severely ill population.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline demographic and clinical characteristics (safety set)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Demographic and clinical characteristics</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Lithium (</bold>
<bold><italic>n</italic></bold>
<bold>= 173)</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Placebo (</bold>
<bold><italic>n</italic></bold>
<bold>= 183)</bold>
</th><th>
<bold>Total (</bold>
<bold><italic>n</italic></bold>
<bold>= 356)</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age (years)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>37.9 (12.7)</td><td>38.8 (12.1)</td><td>38.3 (12.4)</td></tr><tr valign="top"><td>&#x02003;Median</td><td>37.0</td><td>38.0</td><td>37.0</td></tr><tr valign="top"><td>&#x02003;Range (min, max)</td><td>18, 64</td><td>18, 65</td><td>18, 65</td></tr><tr valign="top"><td>Gender, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Male</td><td>101 (58.4)</td><td>121 (66.1)</td><td>222 (62.4)</td></tr><tr valign="top"><td>&#x02003;Female</td><td>72 (41.6)</td><td>62 (33.9)</td><td>134 (37.6)</td></tr><tr valign="top"><td>Race, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;White</td><td>98 (56.6)</td><td>102 (55.7)</td><td>200 (56.2)</td></tr><tr valign="top"><td>&#x02003;Asian</td><td>73 (42.2)</td><td>78 (42.6)</td><td>151 (42.4)</td></tr><tr valign="top"><td>&#x02003;Other</td><td>2 (1.2)</td><td>3 (1.6)</td><td>5 (1.4)</td></tr><tr valign="top"><td>Weight (kg)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>69.1 (15.9)</td><td>71.0 (17.1)</td><td>70.1 (16.5)</td></tr><tr valign="top"><td>&#x02003;Median</td><td>68.0</td><td>69.0</td><td>68.0</td></tr><tr valign="top"><td>&#x02003;Range (min, max)</td><td>37, 120</td><td>37, 115</td><td>37, 120</td></tr><tr valign="top"><td>BMI (kg/m<sup>2</sup>)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>24.3 (4.3)</td><td>24.9 (5.2)</td><td>24.6 (4.8)</td></tr><tr valign="top"><td>&#x02003;Median</td><td>23.8</td><td>24.1</td><td>23.9</td></tr><tr valign="top"><td>&#x02003;Range (min, max)</td><td>15.8, 37.1</td><td>14.7, 43.8</td><td>14.7, 43.8</td></tr><tr valign="top"><td>Psychiatric diagnosis, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Most recent episode manic</td><td>159 (91.8)</td><td>173 (94.5)</td><td>332 (93.3)</td></tr><tr valign="top"><td>&#x02003;Most recent episode mixed</td><td>14 (8.1)</td><td>10 (5.5)</td><td>24 (6.7)</td></tr><tr valign="top"><td>Rapid cycling, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Yes</td><td>3 (1.7)</td><td>5 (2.7)</td><td>8 (2.2)</td></tr><tr valign="top"><td>&#x02003;No</td><td>170 (98.3)</td><td>178 (97.3)</td><td>348 (97.8)</td></tr><tr valign="top"><td>Time since first diagnosis of acute mania, years</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>7.1 (6.6)</td><td>7.8 (7.0)</td><td>7.5 (6.8)</td></tr><tr valign="top"><td>Time since first mania/mixed episode, years</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>7.2 (6.6)</td><td>8.1 (7.0)</td><td>7.7 (6.8)</td></tr><tr valign="top"><td>Total number of mania/mixed episodes in the past year, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;0</td><td>56 (32.4)</td><td>56 (30.6)</td><td>112 (31.5)</td></tr><tr valign="top"><td>&#x02003;1</td><td>88 (50.9)</td><td>88 (48.1)</td><td>176 (49.4)</td></tr><tr valign="top"><td>&#x02003;&#x02265; 2</td><td>29 (16.8)</td><td>39 (21.3)</td><td>68 (19.1)</td></tr><tr valign="top"><td>Previous medication use, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Lithium</td><td>4 (2.3)</td><td>2 (1.1)</td><td>6 (1.7)</td></tr><tr valign="top"><td>&#x02003;Quetiapine</td><td>8 (4.6)</td><td>17 (9.3)</td><td>25 (7.0)</td></tr></tbody></table></table-wrap></p><p>Open-label quetiapine XR was administered at a mean modal dose of 623.1&#x000a0;mg/day (range, 200 to 800&#x000a0;mg/day) in the add-on lithium group and 669.9&#x000a0;mg/day (range, 300 to 900&#x000a0;mg/day) in the add-on placebo group. The mean modal lithium dose was 1,085.5&#x000a0;mg/day (range, 300 to 1,800&#x000a0;mg/day). The mean serum lithium level was 0.72&#x000a0;mEq/L (range, 0.00 to 1.43&#x000a0;mEq/L) at day 43; mean lithium levels did not differ notably during the study (range of means, 0.64 to 0.77&#x000a0;mEq/L). Mean durations of exposure to quetiapine XR were 38.5&#x000a0;days (range, 2 to 48) in the add-on lithium group and 36.9&#x000a0;days (range, 1 to 48) in the add-on placebo group; mean durations of exposure to add-on lithium or placebo were 38.6&#x000a0;days (range, 3 to 48) and 37.2&#x000a0;days (range, 2 to 48), respectively.</p><p>The use of concomitant medications was similar between the lithium (24.9%) and placebo (23.0%) add-on groups, with anilides (acetaminophen) representing the most common concomitant medication in both groups (&#x0003e;3% each) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p><p>A total of 291 (81.7%) patients completed the study, while 65 (18.3%) patients discontinued the study prematurely (<italic>n</italic> = 26 (15.0%), add-on lithium; <italic>n</italic> = 39 (21.3%), add-on placebo group), most commonly because of voluntary discontinuation (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The majority of patients were compliant with quetiapine XR (98.5%, add-on lithium; 94.4%, add-on placebo group) and with lithium (99.2%) or placebo (96.1%).</p><sec id="Sec10"><title>Efficacy assessments</title><sec id="Sec11"><title>Primary efficacy end point</title><p>Mean YMRS total scores decreased from baseline to day 43 in both treatment groups (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Least squares (LS) mean (SE) reductions in YMRS total score were &#x02212;22.8 (0.71) in the add-on lithium and &#x02212;20.1 (0.71) in the add-on placebo group, a significant between-group difference of &#x02212;2.69 (95% CI, &#x02212;4.09 to &#x02212;1.29; <italic>p</italic> &#x0003c; 0.001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Mean change in YMRS total score (with 95% CIs) from baseline (observed case data, ITT set).</bold>
</p></caption><graphic xlink:href="40345_2014_14_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Mean changes from baseline to day 43 in primary and secondary efficacy measures (ITT set)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Measure</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Lithium (</bold>
<bold><italic>n</italic></bold>
<bold>= 173)</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Placebo (</bold>
<bold><italic>n</italic></bold>
<bold>= 176)</bold>
</th></tr></thead><tbody><tr valign="top"><td colspan="3">
<bold>Young Mania Rating Scale (YMRS) total score</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;22.8 (0.71)</td><td>&#x02212;20.1 (0.71)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;2.69 (&#x02212;4.09, &#x02212;1.29)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>&#x0003c;0.001</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;22.6 (7.24)</td><td>&#x02212;20.4 (7.64)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>149</td><td>147</td></tr><tr valign="top"><td colspan="3">
<bold>Clinical Global Impressions Bipolar&#x02013;Severity (CGI-BP-S)</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;2.5 (0.08)</td><td>&#x02212;2.2 (0.08)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;0.24 (&#x02212;0.43, &#x02212;0.04)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>0.017</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;2.5 (0.99)</td><td>&#x02212;2.3 (1.00)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>149</td><td>147</td></tr><tr valign="top"><td colspan="3">
<bold>Clinical Global Impressions Bipolar-Change (CGI-BP-C)</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean (SE) (MMRM)</td><td>1.7 (0.09)</td><td>1.9 (0.09)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;0.20 (&#x02212;0.37, &#x02212;0.03)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>0.020</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean (SD) (OC)</td><td>1.7 (0.69)</td><td>1.9 (0.85)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>149</td><td>147</td></tr><tr valign="top"><td colspan="3">
<bold>Positive and Negative Syndrome Scale (PANSS) total score</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;19.2 (0.91)</td><td>&#x02212;15.6 (0.91)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;3.7 (&#x02212;5.74, &#x02212;1.63)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>&#x0003c;0.001</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;19.8 (12.34)</td><td>&#x02212;16.1 (10.82)</td></tr><tr valign="top"><td>&#x02003;n at Day 43</td><td>148</td><td>147</td></tr><tr valign="top"><td colspan="3">
<bold>PANSS positive subscale</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;8.1 (0.32)</td><td>&#x02212;7.0 (0.32)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;1.1 (&#x02212;1.85, &#x02212;0.39)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>0.003</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;8.1 (4.47)</td><td>&#x02212;7.1 (4.54)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>148</td><td>147</td></tr><tr valign="top"><td>
<bold>PANSS activation subscale</bold>
</td><td/><td/></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;7.1 (0.28)</td><td>&#x02212;5.9 (0.28)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;1.2 (&#x02212;1.77, &#x02212;0.61)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>&#x0003c;0.001</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;7.3 (3.60)</td><td>&#x02212;5.9 (3.77)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>148</td><td>147</td></tr><tr valign="top"><td colspan="3">
<bold>Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) total score</bold>
</td></tr><tr valign="top"><td>&#x02003;LS Mean change (SE) (MMRM)</td><td>&#x02212;4.8 (0.37)</td><td>&#x02212;4.1 (0.37)</td></tr><tr valign="top"><td>&#x02003;Mean difference (95% CI)</td><td align="center" colspan="2">&#x02212;0.6 (&#x02212;1.36, 0.07)</td></tr><tr valign="top"><td>&#x02003;
<italic>p</italic>-value</td><td align="center" colspan="2">
<bold>0.077</bold>
</td></tr><tr valign="top"><td>&#x02003;Mean change (SD) (OC)</td><td>&#x02212;5.0 (4.84)</td><td>&#x02212;4.5 (3.56)</td></tr><tr valign="top"><td>&#x02003;
<italic>n</italic> at day 43</td><td>149</td><td>147</td></tr></tbody></table><table-wrap-foot><p>ITT, intent to treat; LS, least squares; MMRM, mixed-model repeated measures; OC, observed cases. A negative change in score indicates improvement, with the exception of Clinical Global Impressions Bipolar-Change, where a positive change in score indicates improvement. Significant <italic>p</italic>-values shown in bold.</p></table-wrap-foot></table-wrap></p><p>The robustness of the primary efficacy analysis was confirmed by supportive analyses, where significant between-group differences at day 43 were observed in MMRM analysis of the PP set (<italic>p</italic> = 0.005), MMRM modeling of the ITT set with robust variance estimates (<italic>p</italic> &#x0003c; 0.001), and ANCOVA modeling with LOCF methodology (<italic>p</italic> = 0.001).</p><p>In <italic>post hoc</italic> analysis of patients categorized by serum lithium level, LS mean (SE) change in YMRS total score was &#x02212;23.6 (0.79) in the &#x02265;6&#x000a0;mEq/L and &#x02212;21.6 (1.04) in the &#x0003c;6&#x000a0;mEq/L group (<italic>p</italic> &#x0003c; 0.001 and 0.171, respectively, vs. placebo).</p></sec><sec id="Sec12"><title>Secondary efficacy end points</title><p>Response (&#x02265;50% reduction in YMRS score at day 43) occurred in 79.2% and 68.2% of the lithium and placebo add-on groups, respectively, and remission (YMRS total score &#x02264;12 at day 43) was reported in 72.3% and 59.7%, respectively. Between-group differences in response and remission rates were significant in favor of add-on lithium (<italic>p</italic> = 0.005, both). The number needed to treat was 9.1 for response and 7.9 for remission for add-on lithium compared with add-on placebo. The majority of individual YMRS item scores were also significantly improved in the lithium versus the placebo add-on group (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Mean changes in YMRS item scores from baseline (ITT set, MMRM analysis).</bold>
</p></caption><graphic xlink:href="40345_2014_14_Fig3_HTML" id="MO3"/></fig></p><p>In <italic>post hoc</italic> analyses of patients categorized by serum lithium level, response rates were 85.1% and 72.7%, respectively, in the &#x02265;6 and &#x0003c;6&#x000a0;mEq/L groups (<italic>p</italic> = 0.006 and 0.164, respectively, vs. placebo). Remission rates in the respective lithium groups were 78.1% and 65.5% (<italic>p</italic> = 0.004 and 0.170, respectively, vs. placebo).</p><p>Add-on lithium was associated with significantly greater LS mean reductions in CGI-BP-S (mean difference, &#x02212;0.24, <italic>p</italic> = 0.017) and CGI-BP-C (mean difference, &#x02212;0.20; <italic>p</italic> =0.020) than add-on placebo. Proportions of patients &#x02018;much improved&#x02019; or &#x02018;very much improved&#x02019; at day 43 were similar in the two groups (77.5% vs. 71.0%; <italic>p</italic> = 0.177).</p><p>Psychotic features and agitation and aggression, assessed by PANSS total and positive and activation subscales, were improved in both treatment groups, with significantly greater improvements in the add-on lithium than add-on placebo group (<italic>p</italic> &#x0003c; 0.001, 0.003, and &#x0003c; 0.001, for respective scales; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Severity of depressive symptoms, measured by MADRS total score, improved in both groups, without significant between-group difference (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec></sec><sec id="Sec13"><title>Safety and tolerability assessments</title><p>The incidence of TEAEs was 63.0% in the add-on lithium and 48.1% in the add-on placebo group. Tremor, somnolence, dizziness, diarrhea, and vomiting occurred at higher rates in the add-on lithium than add-on placebo group (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Treatment-emergent adverse events in both groups were mostly mild to moderate in intensity.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Incidence of treatment-emergent adverse events (&#x02265;2% in any group; safety set)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Adverse event,</bold>
<bold><italic>n</italic></bold>
<bold>(%)</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Lithium (</bold>
<bold><italic>n</italic></bold>
<bold>= 173)</bold>
</th><th>
<bold>Quetiapine XR&#x02009;+&#x02009;Placebo (</bold>
<bold><italic>n</italic></bold>
<bold>= 183)</bold>
</th></tr></thead><tbody><tr valign="top"><td>Tremor</td><td>27 (15.6)</td><td>9 (4.9)</td></tr><tr valign="top"><td>Somnolence</td><td>22 (12.7)</td><td>10 (5.5)</td></tr><tr valign="top"><td>Constipation</td><td>16 (9.2)</td><td>16 (8.7)</td></tr><tr valign="top"><td>Dry mouth</td><td>14 (8.1)</td><td>14 (7.7)</td></tr><tr valign="top"><td>Dizziness</td><td>11 (6.4)</td><td>8 (4.4)</td></tr><tr valign="top"><td>Insomnia</td><td>11 (6.4)</td><td>12 (6.6)</td></tr><tr valign="top"><td>Headache</td><td>9 (5.2)</td><td>11 (6.0)</td></tr><tr valign="top"><td>Pyrexia</td><td>10 (5.8)</td><td>9 (4.9)</td></tr><tr valign="top"><td>Diarrhea</td><td>8 (4.6)</td><td>2 (1.1)</td></tr><tr valign="top"><td>Vomiting</td><td>8 (4.6)</td><td>0</td></tr><tr valign="top"><td>Sedation</td><td>5 (2.9)</td><td>3 (1.6)</td></tr><tr valign="top"><td>Dysarthria</td><td>4 (2.3)</td><td>2 (1.1)</td></tr><tr valign="top"><td>Nausea</td><td>5 (2.9)</td><td>3 (1.6)</td></tr><tr valign="top"><td>Weight increased</td><td>2 (1.2)</td><td>5 (2.7)</td></tr><tr valign="top"><td>Increased appetite</td><td>4 (2.3)</td><td>1 (0.5)</td></tr></tbody></table><table-wrap-foot><p>Patients with multiple events falling under the same category are counted only once in that category.</p></table-wrap-foot></table-wrap></p><p>Adverse events led to discontinuation in a greater proportion of patients in the add-on placebo than add-on lithium group (<italic>n</italic> = 13 (7.1%) and <italic>n</italic> = 6 (3.5%), respectively). Psychiatric disorders, including mania, were the most common AE leading to discontinuation, reported in two patients in the add-on lithium and seven patients in the placebo add-on group. Serious adverse events (SAEs) included mania (<italic>n</italic> = 3 patients) and gastroenteritis (<italic>n</italic> = 1) in the add-on lithium group and mania (<italic>n</italic> = 6), aggression (<italic>n</italic> = 1), hostility (<italic>n</italic> = 1), and no therapeutic response (<italic>n</italic> = 1) in the add-on placebo group. The SAEs of emergent mania led to study discontinuation in two patients in the add-on lithium and six patients in the add-on placebo group.</p><p>Incidences of TEAEs potentially related to EPS were 16.8% in the add-on lithium and 6.6% in the add-on placebo group, including tremor in 15.6% and 4.9% of patients, respectively. All these TEAEs were mild to moderate in intensity. Two TEAEs (tremor and dystonia) resulted in study discontinuation in the add-on placebo group. The majority of patients showed either improvement or no change in EPS severity during the study, assessed by SAS, AIMS, and BARS scores. For example, SAS score was improved in 11.6% and 8.2% of the add-on lithium and placebo-add groups, respectively, unchanged in 67.1% and 75.4% and worsened in 15.6% and 9.8%, respectively, at day 43. No patients initiated anticholinergic medication for new-onset EPS.</p><p>No TEAEs potentially related to suicidality were reported during the study. Columbia-Suicide Severity Rating Scale assessment identified two patients with suicidal behavior and one with suicidal ideation in the add-on lithium group. Columbia-Suicide Severity Rating Scale and C-CASA assessments at end of treatment indicated that no patients had any type of suicidal ideation in either group. Rates of emergent depression were low in both add-on lithium (1.2%) and add-on placebo (0.5%) groups.</p><p>Among other TEAEs of special interest, there were no reported events potentially related to diabetes mellitus, neutropenia, or QTc prolongation. No clinically meaningful between-group differences were reported in incidences of physical examination, vital signs, hematology, clinical chemistry, or urinalysis findings (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). There were no notable between-group differences in mean changes in liver function parameters, electrolytes, or lipids. The mean change in prolactin concentration was greater in the add-on lithium than add-on placebo group (mean (SD) &#x02013;210.8 (488.1) mU/L vs. &#x02212;116.9 (602.4) mU/L). A greater proportion of patients in the add-on lithium group had weight gain &#x02265;7% at end of treatment compared with add-on placebo (8.0% vs. 4.7%).</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>In this 6-week study, lithium as an add-on therapy to quetiapine XR was significantly more effective than add-on placebo for improving acute severe symptoms of bipolar mania, measured by change in YMRS total score at day 43. Reductions in YMRS score of 22.8 and 20.1, respectively, occurred in the add-on lithium and add-on placebo groups, with a clinically relevant between-group difference of 2.69 in favor of add-on lithium (<italic>p</italic> &#x0003c; 0.001). Consistent with this primary efficacy measure, the secondary efficacy measures showed that add-on lithium significantly improved a range of manic symptoms and the overall severity of illness compared with add-on placebo.</p><p>The combination of quetiapine XR with lithium was generally well tolerated, and reported AEs were consistent with the known safety profiles of these medications in bipolar disorder (Bowden <xref ref-type="bibr" rid="CR4">2000</xref>; Cutler et al. <xref ref-type="bibr" rid="CR7">2011</xref>; Suppes et al. <xref ref-type="bibr" rid="CR37">2010</xref>). In agreement with studies of quetiapine IR (Emsley et al. <xref ref-type="bibr" rid="CR8">2005</xref>), worsening of glycemic control was not observed during quetiapine XR treatment combined with lithium or placebo. Incidences of potentially EPS-related TEAEs were also consistent with studies of quetiapine IR combined with lithium or divalproex (Suppes et al. <xref ref-type="bibr" rid="CR36">2009</xref>; Yatham et al. <xref ref-type="bibr" rid="CR44">2004</xref>). Tremor, a known side effect of lithium (Bowden <xref ref-type="bibr" rid="CR4">2000</xref>), occurred at higher rates in the add-on lithium than add-on placebo group. More patients in the add-on lithium than add-on placebo group also had weight gain &#x02265;7% at the end of treatment. Add-on lithium was not associated with an altered rate of switch to depressive symptoms, which occurred at low incidences in both groups.</p><p>The current study is unique in comparing quetiapine XR combined with lithium against quetiapine XR combined with placebo. Direct comparison with previous studies - which compared a mood stabilizer combined with quetiapine IR against a mood stabilizer combined with placebo - is not possible (Sachs et al. <xref ref-type="bibr" rid="CR28">2004</xref>; Suppes et al. <xref ref-type="bibr" rid="CR36">2009</xref>; Vieta et al. <xref ref-type="bibr" rid="CR41">2008a</xref>; Yatham et al. <xref ref-type="bibr" rid="CR44">2004</xref>), although all these studies indicate the superior efficacy of combination therapy versus monotherapy. In the earlier studies, quetiapine IR combined with a mood stabilizer was significantly more effective than mood stabilizer alone in acute mania (Sachs et al. <xref ref-type="bibr" rid="CR28">2004</xref>; Yatham et al. <xref ref-type="bibr" rid="CR44">2004</xref>) and in the prevention of recurrent mood disorder (Suppes et al. <xref ref-type="bibr" rid="CR36">2009</xref>; Vieta et al. <xref ref-type="bibr" rid="CR41">2008a</xref>). A <italic>post hoc</italic> analysis of the two maintenance studies (Suppes et al. <xref ref-type="bibr" rid="CR36">2009</xref>; Vieta et al. <xref ref-type="bibr" rid="CR41">2008a</xref>) demonstrated that quetiapine IR combined with lithium was associated with a 68% reduction in risk of recurrence of a mood event (manic, depressive, or mixed) compared with placebo and lithium (<italic>p</italic> &#x0003c; 0.001), while quetiapine combined with divalproex reduced recurrence risk by 72% compared with placebo and divalproex (<italic>p</italic> &#x0003c; 0.001) (Suppes et al. <xref ref-type="bibr" rid="CR38">2013</xref>). A second <italic>post hoc</italic> analysis of the maintenance studies showed that quetiapine combined with mood stabilizer (vs. mood stabilizer alone) significantly reduced the risk of recurrence of a mood event, whether the index episode was manic, depressive, or mixed (Vieta et al. <xref ref-type="bibr" rid="CR43">2012</xref>) (<italic>p</italic> &#x02264; 0.001, all). Quetiapine (IR or XR) in combination with lithium or divalproex is also associated with quality-adjusted life expectancy and cost-effectiveness benefits relative to maintenance treatment with mood stabilizers alone (Plosker <xref ref-type="bibr" rid="CR23">2012</xref>). Together, these findings may provide a rationale for initiating treatment with combined quetiapine XR and lithium in patients with severe acute manic symptoms, rather than escalating the dose of monotherapy up to the highest dose approved, and hence also for subsequent use of this combination as maintenance treatment to prevent recurrence.</p><p>Notable features of this study include the initiation of medications (quetiapine XR and lithium or placebo) concurrently at the start of the study, which reflects management of severe acute mania in practice. To demonstrate efficacy for combination therapy in this setting is challenging, when compared with study of patients who show partial response to monotherapy. This study also required an inpatient status at randomization, which provides reassurance on the reliability of YMRS and other scoring at baseline.</p><p>Direct comparison of the quetiapine XR and lithium combination versus other combination therapies in acute mania is hampered by the limited availability of other studies and differences in study design, duration, and patient population. Most studies report superior efficacy for combinations versus monotherapy (measured as symptom control, speed of onset, or relapse prevention), but also increased rates of AEs and related discontinuations (Geoffroy et al. <xref ref-type="bibr" rid="CR11">2012</xref>). For example, when compared with a mood stabilizer alone, combinations including a mood stabilizer and olanzapine or asenapine are associated with weight gain, combinations including aripiprazole lead to greater risk of akathisia, and combinations including quetiapine are associated with increased somnolence (Geoffroy et al. <xref ref-type="bibr" rid="CR11">2012</xref>; Sachs et al. <xref ref-type="bibr" rid="CR28">2004</xref>; Szegedi et al. <xref ref-type="bibr" rid="CR39">2012</xref>; Tohen et al. <xref ref-type="bibr" rid="CR40">2002</xref>; Vieta et al. <xref ref-type="bibr" rid="CR42">2008b</xref>; Yatham et al. <xref ref-type="bibr" rid="CR44">2004</xref>). While the quetiapine XR and lithium combination in the current study was associated with elevated rates of tremor and somnolence when compared with quetiapine alone, the combination was generally well tolerated and rates of treatment-related discontinuations were below add-on placebo-group levels.</p><p>This study raises a number of questions that would require further investigation. Add-on lithium showed significant benefits despite a high proportion of patients (approximately 65%) having serum lithium levels outside the target range. The target lithium range selected (0.8 to 1.2&#x000a0;mEq/L) was based on evidence for the efficacy of lithium as monotherapy in bipolar disorder (Goodwin and Jamison <xref ref-type="bibr" rid="CR13">2007</xref>). <italic>Post hoc</italic> analyses in the current study reported greater efficacy (assessed as YMRS score change, response rate, and remission rate) for add-on lithium versus add-on placebo at a lithium level &#x02265;6&#x000a0;mEq/L, but not &#x0003c;6&#x000a0;mEq/L. These data are consistent with an earlier study that reported significant efficacy against manic symptoms for lithium monotherapy versus placebo at higher (0.72 and 0.5&#x000a0;mEq/kg/day) but not lower (0.24&#x000a0;mEq/kg/day) lithium doses (Stokes et al. <xref ref-type="bibr" rid="CR35">1976</xref>). It may also be conjectured that the use of lower quetiapine doses in the add-on lithium than add-on placebo group (mean modal 623.1&#x000a0;mg/day vs. 669.9&#x000a0;mg/day) contributed to reduce the between-group difference in YMRS score. Investigators may have judged that there was no requirement to increase the quetiapine dose in a substantial proportion of patients due to the effective control of manic symptoms achieved by the addition of blinded lithium. Furthermore, the lower doses of quetiapine used in the add-on lithium group may have contributed to the beneficial side effect profile of combination therapy observed in this study.</p><p>The study design excluded patients with a known lack of response to lithium or quetiapine, although only 1.7% and 7.0%, respectively, of the study population were treated with lithium and quetiapine previously. The benefits of combination therapy in lithium nonresponders are therefore unknown from this study, although other studies (Hardoy et al. <xref ref-type="bibr" rid="CR16">2005</xref>; Yatham et al. <xref ref-type="bibr" rid="CR44">2004</xref>) have suggested that lithium nonresponders may benefit from combination therapy with quetiapine and lithium. The pharmacological rationale for combining quetiapine and lithium also remains to be confirmed, although it may be conjectured that the mechanisms of action of quetiapine (Nemeroff et al. <xref ref-type="bibr" rid="CR19">2002</xref>; Nord et al. <xref ref-type="bibr" rid="CR21">2011</xref>) and lithium (Quiroz et al. <xref ref-type="bibr" rid="CR26">2010</xref>; Shim et al. <xref ref-type="bibr" rid="CR31">2012</xref>) are complementary and additive as combination therapy.</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusions</title><p>Add-on lithium enhanced the efficacy of quetiapine XR in patients with acute bipolar I mania, without compromising safety and tolerability.</p></sec></body><back><app-group><app id="App1"><sec id="Sec16"><title>Additional file</title><p><media position="anchor" xlink:href="40345_2014_14_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1: Tables S1 to S2.</label><caption><p>
<bold>Table S1.</bold> Use of concomitant medications (safety set). <bold>Table S2.</bold> Incidence (<italic>n</italic> (%)) of potentially clinically significant shifts in vital signs and laboratory parameters from normal at baseline to day 43 (safety set).</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>AIMS</term><def><p>abnormal involuntary movement scale</p></def></def-item><def-item><term>ANCOVA</term><def><p>analysis of covariance</p></def></def-item><def-item><term>BARS</term><def><p>Barnes Akathisia Rating Scale</p></def></def-item><def-item><term>C-CASA</term><def><p>Columbia-Classification Algorithm for Suicide Assessment</p></def></def-item><def-item><term>CGI-BP</term><def><p>Clinical Global Impressions for Bipolar Disorder</p></def></def-item><def-item><term>CGI-BP-C</term><def><p>CGI-BP-Change</p></def></def-item><def-item><term>CGI-BP-S</term><def><p>CGI-BP-Severity of Illness</p></def></def-item><def-item><term>C-SSRS</term><def><p>Columbia-Suicide Severity Rating Scale</p></def></def-item><def-item><term><italic>DSM-IV-TR</italic></term><def><p><italic>Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision</italic></p></def></def-item><def-item><term>EPS</term><def><p>extrapyramidal symptoms</p></def></def-item><def-item><term>IR</term><def><p>immediate release</p></def></def-item><def-item><term>ITT</term><def><p>intent-to-treat</p></def></def-item><def-item><term>LOCF</term><def><p>last-observation-carried-forward</p></def></def-item><def-item><term>LS</term><def><p>least squares</p></def></def-item><def-item><term>MMRM</term><def><p>mixed-model for repeated measures</p></def></def-item><def-item><term>PANSS</term><def><p>positive and negative syndrome scale</p></def></def-item><def-item><term>PP</term><def><p>per protocol</p></def></def-item><def-item><term>TEAE</term><def><p>treatment-emergent adverse events</p></def></def-item><def-item><term>XR</term><def><p>extended release</p></def></def-item><def-item><term>YMRS</term><def><p>Young Mania Rating Scale</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>Michel S. Bourin has served as a consultant for Servier and Lundbeck. Emanuel Severus has been on the speakership bureaus of AstraZeneca, Eli Lilly and Company, and Lundbeck. Juan P. Schronen has served as a consultant for Janssen and Servier. Peter Gass has been on the speakership bureaus/advisory boards of Pfizer and Servier. Johan Szamosi was a full-time employee and a stock shareholder of AstraZeneca at the time the study was performed. Hans A. Eriksson was a full-time employee and a stock shareholder of AstraZeneca at the time the study was performed. He holds AstraZeneca patent US20070185080A1. Hongally Chandrashekar has no disclosures to report.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MSB participated in the design of the trial, was the principal investigator, and took part in the writing of the draft. ES took part in the clinical trial as LKP for Germany and helped to draft the manuscript. JPS was a principal investigator on the study and took part in writing of the draft. PG contributed significantly in the acquisition of data and in drafting and revising the article. JS had overall responsibility for the statistical analyses for the study. HAE participated in the conception and design of the study, interpretation of the results, and drafting of the manuscript. HC took part as an investigator in the trial in India and helped to draft the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Bill Wolvey, BSc, of PAREXEL for medical writing support, which was funded by AstraZeneca.</p><sec id="d30e2168"><title>Funding support</title><p>This study was funded by AstraZeneca Pharmaceuticals.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision</source><year>2000</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>TR</given-names></name></person-group><article-title>A rating scale for drug-induced akathisia</article-title><source>Br J Psychiatry</source><year>1989</year><volume>154</volume><fpage>672</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1192/bjp.154.5.672</pub-id><pub-id pub-id-type="pmid">2574607</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourin</surname><given-names>M</given-names></name><name><surname>Thibaut</surname><given-names>F</given-names></name></person-group><article-title>How to assess drugs in the treatment of acute bipolar mania?</article-title><source>Front Pharmacol (Online ahead of print)</source><year>2013</year><volume>4</volume><fpage>4</fpage></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>CL</given-names></name></person-group><article-title>Efficacy of lithium in mania and maintenance therapy of bipolar disorder</article-title><source>J Clin Psychiatry</source><year>2000</year><volume>61</volume><issue>suppl 9</issue><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10826659</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>JO</given-names><suffix>III</suffix></name><name><surname>Goldberg</surname><given-names>JF</given-names></name><name><surname>Ketter</surname><given-names>TA</given-names></name><name><surname>Miklowitz</surname><given-names>DJ</given-names></name><name><surname>Calabrese</surname><given-names>JR</given-names></name><name><surname>Bowden</surname><given-names>CL</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name></person-group><article-title>Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder</article-title><source>J Clin Psychiatry</source><year>2011</year><volume>72</volume><issue>2</issue><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.4088/JCP.09m05214yel</pub-id><pub-id pub-id-type="pmid">20868629</pub-id></element-citation></ref><ref id="CR6"><mixed-citation publication-type="other">Connolly KR, Thase ME (2011) The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 13(4)&#x0115f;.</mixed-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname><given-names>AJ</given-names></name><name><surname>Datto</surname><given-names>C</given-names></name><name><surname>Nordenhem</surname><given-names>A</given-names></name><name><surname>Minkwitz</surname><given-names>M</given-names></name><name><surname>Acevedo</surname><given-names>L</given-names></name><name><surname>Darko</surname><given-names>D</given-names></name></person-group><article-title>Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial</article-title><source>Clin Ther</source><year>2011</year><volume>33</volume><issue>11</issue><fpage>1643</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2011.10.002</pub-id><pub-id pub-id-type="pmid">22054797</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>R</given-names></name><name><surname>Turner</surname><given-names>HJ</given-names></name><name><surname>Schronen</surname><given-names>J</given-names></name><name><surname>Botha</surname><given-names>K</given-names></name><name><surname>Smit</surname><given-names>R</given-names></name><name><surname>Oosthuizen</surname><given-names>PP</given-names></name></person-group><article-title>Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial</article-title><source>Int J Neuropsychopharmacol</source><year>2005</year><volume>8</volume><issue>2</issue><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1017/S1461145705005067</pub-id><pub-id pub-id-type="pmid">15737251</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Williams</surname><given-names>JBW</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name></person-group><source>Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT)</source><year>2007</year><publisher-loc>New York</publisher-loc><publisher-name>Biometrics Research, New York State Psychiatric Institute</publisher-name></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlow</surname><given-names>SJ</given-names></name></person-group><article-title>Interventions for acute mood episodes in patients with bipolar disorder</article-title><source>J Clin Psychiatry</source><year>2008</year><volume>69</volume><issue>2</issue><fpage>e05</fpage><pub-id pub-id-type="doi">10.4088/JCP.0208e05</pub-id><pub-id pub-id-type="pmid">18363449</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geoffroy</surname><given-names>PA</given-names></name><name><surname>Etain</surname><given-names>B</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Bellivier</surname><given-names>F</given-names></name></person-group><article-title>Combination therapy for manic phases: a critical review of a common practice</article-title><source>CNS Neurosci Ther</source><year>2012</year><volume>18</volume><issue>12</issue><fpage>957</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1111/cns.12017</pub-id><pub-id pub-id-type="pmid">23095277</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>GM</given-names></name></person-group><article-title>Evidence-based guidelines for treating bipolar disorder: revised second edition&#x02013;recommendations from the British Association for Psychopharmacology</article-title><source>J Psychopharmacol</source><year>2009</year><volume>23</volume><issue>4</issue><fpage>346</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1177/0269881109102919</pub-id><pub-id pub-id-type="pmid">19329543</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>FK</given-names></name><name><surname>Jamison</surname><given-names>KR</given-names></name></person-group><source>Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression</source><year>2007</year><edition>2</edition><publisher-loc>New York</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunze</surname><given-names>H</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name><name><surname>Bowden</surname><given-names>C</given-names></name><name><surname>Licht</surname><given-names>RW</given-names></name><name><surname>Moller</surname><given-names>HJ</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name></person-group><article-title>The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania</article-title><source>World J Biol Psychiatry</source><year>2009</year><volume>10</volume><issue>2</issue><fpage>85</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1080/15622970902823202</pub-id><pub-id pub-id-type="pmid">19347775</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>ECDEU Assessment Manual for Psychopharmacology. Revised Edition</source><year>1976</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>US Department of Health, Education and Welfare</publisher-name></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardoy</surname><given-names>MC</given-names></name><name><surname>Garofalo</surname><given-names>A</given-names></name><name><surname>Carpiniello</surname><given-names>B</given-names></name><name><surname>Calabrese</surname><given-names>JR</given-names></name><name><surname>Carta</surname><given-names>MG</given-names></name></person-group><article-title>Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder</article-title><source>Clin Pract Epidemiol Ment Health</source><year>2005</year><volume>1</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-1-7</pub-id><pub-id pub-id-type="pmid">16026618</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name></person-group><article-title>The positive and negative syndrome scale (PANSS) for schizophrenia</article-title><source>Schizophr Bull</source><year>1987</year><volume>13</volume><issue>2</issue><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id><pub-id pub-id-type="pmid">3616518</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Asberg</surname><given-names>M</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change</article-title><source>Br J Psychiatry</source><year>1979</year><volume>134</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id><pub-id pub-id-type="pmid">444788</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>CB</given-names></name><name><surname>Kinkead</surname><given-names>B</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name></person-group><article-title>Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing</article-title><source>J Clin Psychiatry</source><year>2002</year><volume>63</volume><issue>suppl 13</issue><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12562141</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nivoli</surname><given-names>AM</given-names></name><name><surname>Colom</surname><given-names>F</given-names></name><name><surname>Murru</surname><given-names>A</given-names></name><name><surname>Pacchiarotti</surname><given-names>I</given-names></name><name><surname>Castro-Loli</surname><given-names>P</given-names></name><name><surname>Gonzalez-Pinto</surname><given-names>A</given-names></name><name><surname>Fountoulakis</surname><given-names>KN</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name></person-group><article-title>New treatment guidelines for acute bipolar depression: a systematic review</article-title><source>J Affect Disord</source><year>2011</year><volume>129</volume><issue>1&#x02013;3</issue><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2010.05.018</pub-id><pub-id pub-id-type="pmid">20538341</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nord</surname><given-names>M</given-names></name><name><surname>Nyberg</surname><given-names>S</given-names></name><name><surname>Brogren</surname><given-names>J</given-names></name><name><surname>Jucaite</surname><given-names>A</given-names></name><name><surname>Halldin</surname><given-names>C</given-names></name><name><surname>Farde</surname><given-names>L</given-names></name></person-group><article-title>Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects</article-title><source>Int J Neuropsychopharmacol</source><year>2011</year><volume>14</volume><issue>10</issue><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1017/S1461145711000514</pub-id><pub-id pub-id-type="pmid">21477416</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oral</surname><given-names>TE</given-names></name></person-group><article-title>Treatment of acute mania</article-title><source>Neuro Endocrinol Lett</source><year>2005</year><volume>26</volume><issue>suppl 1</issue><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16361986</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plosker</surname><given-names>GL</given-names></name></person-group><article-title>Quetiapine: a pharmacoeconomic review of its use in bipolar disorder</article-title><source>Pharmacoeconomics</source><year>2012</year><volume>30</volume><issue>7</issue><fpage>611</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.2165/11208500-000000000-00000</pub-id><pub-id pub-id-type="pmid">22559293</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><name><surname>Gould</surname><given-names>M</given-names></name><name><surname>Stanley</surname><given-names>B</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name></person-group><article-title>Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><issue>7</issue><fpage>1035</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.164.7.1035</pub-id><pub-id pub-id-type="pmid">17606655</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Stanley</surname><given-names>B</given-names></name><name><surname>Brent</surname><given-names>DA</given-names></name><name><surname>Yershova</surname><given-names>KV</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><name><surname>Currier</surname><given-names>GW</given-names></name><name><surname>Melvin</surname><given-names>GA</given-names></name><name><surname>Greenhill</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name></person-group><article-title>The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults</article-title><source>Am J Psychiatry</source><year>2011</year><volume>168</volume><issue>12</issue><fpage>1266</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2011.10111704</pub-id><pub-id pub-id-type="pmid">22193671</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiroz</surname><given-names>JA</given-names></name><name><surname>Machado-Vieira</surname><given-names>R</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Manji</surname><given-names>HK</given-names></name></person-group><article-title>Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects</article-title><source>Neuropsychobiology</source><year>2010</year><volume>62</volume><issue>1</issue><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1159/000314310</pub-id><pub-id pub-id-type="pmid">20453535</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>GS</given-names></name><name><surname>Gardner-Schuster</surname><given-names>EE</given-names></name></person-group><article-title>Adjunctive treatment of acute mania: a clinical overview</article-title><source>Acta Psychiatr Scand Suppl</source><year>2007</year><volume>434</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.2007.01056.x</pub-id><pub-id pub-id-type="pmid">17688460</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>G</given-names></name><name><surname>Chengappa</surname><given-names>KN</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Mullen</surname><given-names>JA</given-names></name><name><surname>Brecher</surname><given-names>M</given-names></name><name><surname>Devine</surname><given-names>NA</given-names></name><name><surname>Sweitzer</surname><given-names>DE</given-names></name></person-group><article-title>Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study</article-title><source>Bipolar Disord</source><year>2004</year><volume>6</volume><issue>3</issue><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2004.00115.x</pub-id><pub-id pub-id-type="pmid">15117400</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Moreno</surname><given-names>J</given-names></name><name><surname>Martinez-Aran</surname><given-names>A</given-names></name><name><surname>Tabares-Seisdedos</surname><given-names>R</given-names></name><name><surname>Torrent</surname><given-names>C</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Ayuso-Mateos</surname><given-names>JL</given-names></name></person-group><article-title>Functioning and disability in bipolar disorder: an extensive review</article-title><source>Psychother Psychosom</source><year>2009</year><volume>78</volume><issue>5</issue><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1159/000228249</pub-id><pub-id pub-id-type="pmid">19602917</pub-id></element-citation></ref><ref id="CR30"><mixed-citation publication-type="other">Seroquel XR (quetiapine fumarate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. Available at: <ext-link ext-link-type="uri" xlink:href="http://www1.astrazeneca-us.com/pi/seroquelxr.pdf">http://www1.astrazeneca-us.com/pi/seroquelxr.pdf</ext-link>; 2013.</mixed-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>SS</given-names></name><name><surname>Hammonds</surname><given-names>MD</given-names></name><name><surname>Tatsuoka</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>IJ</given-names></name></person-group><article-title>Effects of 4-weeks of treatment with lithium and olanzapine on long-term potentiation in hippocampal area CA1</article-title><source>Neurosci Lett</source><year>2012</year><volume>524</volume><issue>1</issue><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2012.06.047</pub-id><pub-id pub-id-type="pmid">22750162</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>GM</given-names></name><name><surname>Angus</surname><given-names>JW</given-names></name></person-group><article-title>A rating scale for extrapyramidal side effects</article-title><source>Acta Psychiatr Scand Suppl</source><year>1970</year><volume>212</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1970.tb02066.x</pub-id><pub-id pub-id-type="pmid">4917967</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>Cornelius</surname><given-names>V</given-names></name><name><surname>Warnock</surname><given-names>A</given-names></name><name><surname>Tacchi</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials</article-title><source>Bipolar Disord</source><year>2007</year><volume>9</volume><issue>6</issue><fpage>551</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2007.00468.x</pub-id><pub-id pub-id-type="pmid">17845269</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spearing</surname><given-names>MK</given-names></name><name><surname>Post</surname><given-names>RM</given-names></name><name><surname>Leverich</surname><given-names>GS</given-names></name><name><surname>Brandt</surname><given-names>D</given-names></name><name><surname>Nolen</surname><given-names>W</given-names></name></person-group><article-title>Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP</article-title><source>Psychiatry Res</source><year>1997</year><volume>73</volume><issue>3</issue><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0165-1781(97)00123-6</pub-id><pub-id pub-id-type="pmid">9481807</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>PE</given-names></name><name><surname>Kocsis</surname><given-names>JH</given-names></name><name><surname>Arcuni</surname><given-names>OJ</given-names></name></person-group><article-title>Relationship of lithium chloride dose to treatment response in acute mania</article-title><source>Arch Gen Psychiatry</source><year>1976</year><volume>33</volume><issue>9</issue><fpage>1080</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1976.01770090070006</pub-id><pub-id pub-id-type="pmid">17642108</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Brecher</surname><given-names>M</given-names></name><name><surname>Paulsson</surname><given-names>B</given-names></name></person-group><article-title>Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127)</article-title><source>Am J Psychiatry</source><year>2009</year><volume>166</volume><issue>4</issue><fpage>476</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08020189</pub-id><pub-id pub-id-type="pmid">19289454</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Datto</surname><given-names>C</given-names></name><name><surname>Minkwitz</surname><given-names>M</given-names></name><name><surname>Nordenhem</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Darko</surname><given-names>D</given-names></name></person-group><article-title>Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression</article-title><source>J Affect Disord</source><year>2010</year><volume>121</volume><issue>1&#x02013;2</issue><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2009.10.007</pub-id><pub-id pub-id-type="pmid">19903574</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Gustafsson</surname><given-names>U</given-names></name><name><surname>Ekholm</surname><given-names>B</given-names></name></person-group><article-title>Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials</article-title><source>Depress Anxiety</source><year>2013</year><volume>30</volume><issue>11</issue><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1002/da.22136</pub-id><pub-id pub-id-type="pmid">23761037</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szegedi</surname><given-names>A</given-names></name><name><surname>Calabrese</surname><given-names>JR</given-names></name><name><surname>Stet</surname><given-names>L</given-names></name><name><surname>Mackle</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Panagides</surname><given-names>J</given-names></name></person-group><article-title>Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension</article-title><source>J Clin Psychopharmacol</source><year>2012</year><volume>32</volume><issue>1</issue><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e31823f872f</pub-id><pub-id pub-id-type="pmid">22198448</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohen</surname><given-names>M</given-names></name><name><surname>Chengappa</surname><given-names>KN</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Calabrese</surname><given-names>JR</given-names></name><name><surname>Bowden</surname><given-names>CL</given-names></name><name><surname>Sachs</surname><given-names>GS</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Baker</surname><given-names>RW</given-names></name><name><surname>Risser</surname><given-names>RC</given-names></name><name><surname>Keeter</surname><given-names>EL</given-names></name><name><surname>Feldman</surname><given-names>PD</given-names></name><name><surname>Tollefson</surname><given-names>GD</given-names></name><name><surname>Breier</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy</article-title><source>Arch Gen Psychiatry</source><year>2002</year><volume>59</volume><issue>1</issue><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.59.1.62</pub-id><pub-id pub-id-type="pmid">11779284</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Eggens</surname><given-names>I</given-names></name><name><surname>Persson</surname><given-names>I</given-names></name><name><surname>Paulsson</surname><given-names>B</given-names></name><name><surname>Brecher</surname><given-names>M</given-names></name></person-group><article-title>Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)</article-title><source>J Affect Disord</source><year>2008</year><volume>109</volume><issue>3</issue><fpage>251</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2008.06.001</pub-id><pub-id pub-id-type="pmid">18579216</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>T&#x02019;joen</surname><given-names>C</given-names></name><name><surname>McQuade</surname><given-names>RD</given-names></name><name><surname>Carson</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Marcus</surname><given-names>RN</given-names></name><name><surname>Sanchez</surname><given-names>R</given-names></name><name><surname>Owen</surname><given-names>R</given-names></name><name><surname>Nameche</surname><given-names>L</given-names></name></person-group><article-title>Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study</article-title><source>Am J Psychiatry</source><year>2008</year><volume>165</volume><issue>10</issue><fpage>1316</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07101560</pub-id><pub-id pub-id-type="pmid">18381903</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Ekholm</surname><given-names>B</given-names></name><name><surname>Udd</surname><given-names>M</given-names></name><name><surname>Gustafsson</surname><given-names>U</given-names></name></person-group><article-title>Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder</article-title><source>J Affect Disord</source><year>2012</year><volume>142</volume><issue>1&#x02013;3</issue><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2012.04.014</pub-id><pub-id pub-id-type="pmid">23062763</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>LN</given-names></name><name><surname>Paulsson</surname><given-names>B</given-names></name><name><surname>Mullen</surname><given-names>J</given-names></name><name><surname>Vagero</surname><given-names>AM</given-names></name></person-group><article-title>Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania</article-title><source>J Clin Psychopharmacol</source><year>2004</year><volume>24</volume><issue>6</issue><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1097/01.jcp.0000144887.66319.2f</pub-id><pub-id pub-id-type="pmid">15538120</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatham</surname><given-names>LN</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Schaffer</surname><given-names>A</given-names></name><name><surname>Parikh</surname><given-names>SV</given-names></name><name><surname>Beaulieu</surname><given-names>S</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>C</given-names></name><name><surname>MacQueen</surname><given-names>G</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>LT</given-names></name><name><surname>Young</surname><given-names>AH</given-names></name><name><surname>Alda</surname><given-names>M</given-names></name><name><surname>Milev</surname><given-names>R</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Calabrese</surname><given-names>JR</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Ha</surname><given-names>K</given-names></name><name><surname>Kapczinski</surname><given-names>F</given-names></name></person-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009</article-title><source>Bipolar Disord</source><year>2009</year><volume>11</volume><issue>3</issue><fpage>225</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2009.00672.x</pub-id><pub-id pub-id-type="pmid">19419382</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>RC</given-names></name><name><surname>Biggs</surname><given-names>JT</given-names></name><name><surname>Ziegler</surname><given-names>VE</given-names></name><name><surname>Meyer</surname><given-names>DA</given-names></name></person-group><article-title>A rating scale for mania: reliability, validity and sensitivity</article-title><source>Br J Psychiatry</source><year>1978</year><volume>133</volume><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1192/bjp.133.5.429</pub-id><pub-id pub-id-type="pmid">728692</pub-id></element-citation></ref></ref-list></back></article>